Wei Sheng Yan Jiu
In order to be eligible, you need to meet a certain BMI 30 or above, or 27 with another specific medical condition such as hypertension, dyslipidemia, type 2 diabetes, prediabetes, non-alcoholic fatty liver disease, polycystic ovarian syndrome, heart disease, or obstructive sleep apnea
Clinical trials consistently show that Wegovy leads to greater average weight loss compared to other forms of semaglutide, including Ozempic and Rybelsus, which are primarily used as diabetes drugs to help control blood sugar levels in patients with type 2 diabetes
These medications have been shown to lead to significantly lower self-reported hunger, reduced food intake, and increased awareness around hunger cues and eating in response to environmental or emotional triggers
Emerging Obesity Drugs and Diabetes Drug Pipeline 2025 in the U.S
Here are some significant clinical trials that give evidence for semaglutide's long-term weight loss benefits: Semaglutide Treatment Effect in People with Obesity (STEP) Trials : The STEP program consisted of four phase 3 clinical trials (STEP 1, STEP 2, STEP 3, and STEP 4) that evaluated the efficacy and safety of semaglutide for weight management